BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 22183078)

  • 1. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
    Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
    Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI.
    De Cobelli F; Esposito A; Perseghin G; Sallemi C; Belloni E; Ravelli S; Lanzani C; Del Maschio A
    AJR Am J Roentgenol; 2012 Apr; 198(4):809-16. PubMed ID: 22451545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
    Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
    Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine.
    Wagner M; Schilling R; Doeblin P; Huppertz A; Luhur R; Schwenke C; Maurer M; Hamm B; Taupitz M; Durmus T
    Eur Radiol; 2013 Jan; 23(1):108-14. PubMed ID: 22772150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
    Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
    J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual comparison of T1 relaxation times after gadobutrol and Gd-DTPA administration for cardiac late enhancement imaging.
    Doeblin P; Schilling R; Wagner M; Luhur R; Huppertz A; Hamm B; Taupitz M; Durmus T
    Eur J Radiol; 2014 Apr; 83(4):660-4. PubMed ID: 24433640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T.
    Wildgruber M; Stadlbauer T; Rasper M; Hapfelmeier A; Zelger O; Eckstein HH; Halle M; Rummeny EJ; Huber AM
    Invest Radiol; 2014 Nov; 49(11):728-34. PubMed ID: 24872002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing dose and administration regimen of a high-relaxivity contrast agent for myocardial MRI late gadolinium enhancement.
    Secchi F; Di Leo G; Papini GD; Giacomazzi F; Di Donato M; Sardanelli F
    Eur J Radiol; 2011 Oct; 80(1):96-102. PubMed ID: 20638210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.
    Giesel FL; Mehndiratta A; Risse F; Rius M; Zechmann CM; von Tengg-Kobligk H; Gerigk L; Kauczor HU; Politi M; Essig M; Griffiths PD; Wilkinson ID
    Acta Radiol; 2009 Jun; 50(5):521-30. PubMed ID: 19337867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs.
    Hadizadeh DR; Jost G; Pietsch H; Weibrecht M; Perkuhn M; Boschewitz JM; Keil VC; Träber F; Kukuk GM; Schild HH; Willinek WA
    Invest Radiol; 2014 Jul; 49(7):457-64. PubMed ID: 24598442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate.
    Schlosser T; Hunold P; Herborn CU; Lehmkuhl H; Lind A; Massing S; Barkhausen J
    Radiology; 2005 Sep; 236(3):1041-6. PubMed ID: 16055693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
    Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
    Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine.
    Fink C; Bock M; Kiessling F; Lichy MP; Krissak R; Zuna I; Schmähl A; Delorme S; Kauczor HU
    J Magn Reson Imaging; 2004 Feb; 19(2):202-8. PubMed ID: 14745754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla.
    Klumpp B; Fenchel M; Hoevelborn T; Helber U; Scheule A; Claussen C; Miller S
    Invest Radiol; 2006 Sep; 41(9):661-7. PubMed ID: 16896300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Prokop M; Schneider G; Vanzulli A; Goyen M; Ruehm SG; Douek P; Daprà M; Pirovano G; Kirchin MA; Spinazzi A
    Radiology; 2005 Feb; 234(2):399-408. PubMed ID: 15616119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.